W. Parker

发表

Cybrids in Alzheimer's disease: A cellular model of the disease?

R. Davis, R. Swerdlow, J. Parks, 1997, Neurology.

Cytochrome oxidase deficiency in Alzheimer's disease

C. Filley, J. Parks, W. Parker, 1990, Neurology.

Secondary inhibition of 2‐ketoglutarate dehydrogenase complex by MPTP

W. Parker, G. Joffe, J. Parks, 1998, Neuroreport.

Preclinical detection of Parkinson's disease

W. Parker, 1991, Neurology.

Effects of memantine on mitochondrial function.

R. Swerdlow, W. Parker, Sangeeta Ghosh, 2008, Biochemical pharmacology.

Further Evidence for Mitochondrial Dysfunction in Progressive Supranuclear Palsy

Russell H. Swerdlow, M. Beal, R. Swerdlow, 2001, Experimental Neurology.

Mitochondria in Sporadic Amyotrophic Lateral Sclerosis

Gary L. Pattee, R. Swerdlow, J. Sheehan, 1998, Experimental Neurology.

Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy

I. Litvan, G. Wooten, L. Golbe, 2000, Journal of neurochemistry.

Mitochondrial abnormalities in non-alcoholic steatohepatitis.

J. Parks, W. Parker, S. Caldwell, 1999, Journal of hepatology.

Risk factors for schizophrenia [2] (multiple letters)

P. McGuffin, I. Gottesman, H. Ewald, 1999 .

Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA‐receptor and nitric‐oxide‐synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro

J. Parks, J. Bennett, W. Parker, 2001, Journal of neurochemistry.

Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions.

A. Luder, J. Parks, W. Parker, 1990, The Journal of clinical investigation.

Complex I deficiency in Parkinson's disease frontal cortex

R. Swerdlow, J. Parks, W. Parker, 2008, Brain Research.

Mitochondrial pathology in Parkinson's disease and implications for therapeutic intervention

R. Swerdlow, W. Parker, R. Swerdlow, 1999 .

MITOCHONDRIAL GENETICS ’98 Mitochondrial Dysfunction in Idiopathic Parkinson Disease

R. Swerdlow, W. Parker, 1998 .

Abnormalities of the electron transport chain in idiopathic parkinson's disease

J. Parks, W. Parker, S. Boyson, 1989, Annals of neurology.

Disrupted mitochondrial electron transport function increases expression of anti‐apoptotic Bcl‐2 and Bcl‐XL proteins in SH‐SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress

C. Fall, R. Swerdlow, J. Bennett, 2000, Journal of neuroscience research.

The other genome.

W. Parker, W Davis Parker Jr, 1999, Clinical chemistry.

Mitochondrial Dysfunction in Parkinson’s Disease: Potential Applications for Cybrid Modeling of the Disease

R. Swerdlow, G. Wooten, J. Parks, 1998 .

Maternal inheritance in Parkinson's disease

G. Wooten, J. Bennett, W. Parker, 1997, Annals of neurology.

Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.

C. Fall, R. Swerdlow, D. Cassarino, 1997, Biochimica et biophysica acta.

Myxothiazol resistance in human mitochondria.

J. Parks, W. Parker, F. Frerman, 1988, Biochimica et biophysica acta.

Brain mitochondrial metabolism in experimental thiamine deficiency

J. Parks, W. Parker, D. Stumpf, 1984, Neurology.

Origin and functional consequences of the complex I defect in Parkinson's disease

R. Swerdlow, J. Sheehan, J. Parks, 1996, Annals of neurology.

Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids.

R. Swerdlow, J. Parks, D. Cassarino, 1998, Biochemical and biophysical research communications.

Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles.

J. Parks, W. Parker, S. Eaton, 1994, Archives of biochemistry and biophysics.

Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase.

J. Bennett, W. Parker, R. Swerdlow, 1994, Neuroreport.

Effects of octanoate on rat brain and liver mitochondria

W. Parker, D. Stumpf, R. Haas, 1983, Neurology.

Carnitine deficiency with valproate therapy.

W. Parker, D. Stumpf, R. Haas, 1983, The Journal of pediatrics.

Carnitine deficiency, organic acidemias, and Reye's syndrome

C. Angelini, W. Parker, D. Stumpf, 1985, Neurology.

Association of the mitochondrial 8344 MERRF mutation with maternally inherited spinocerebellar degeneration and Leigh disease

N. Howell, I. Kubacka, J. Parks, 1996, Neurology.

Risk factors for schizophrenia.

R. Swerdlow, W. Parker, D. Binder, 1999, The New England journal of medicine.

Phenotypic variation in biotinidase deficiency.

W. Parker, B. Wolf, S. Goodman, 1983, The Journal of pediatrics.

Friedreich's disease

J. Parks, W. Parker, D. Stumpf, 1983, Neurology.

Deficient biotinidase activity in late-onset multiple carboxylase deficiency.

W. Parker, B. Wolf, S. Goodman, 1983, The New England journal of medicine.

Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines

R. Swerdlow, J. Parks, J. Bennett, 2000, Experimental Neurology.

Calcium Homeostasis and Reactive Oxygen Species Production in Cells Transformed by Mitochondria from Individuals with Sporadic Alzheimer’s Disease

Jason P. Sheehan, R. Swerdlow, J. Sheehan, 1997, The Journal of Neuroscience.

Mitochondrial function after asphyxia in newborn lambs.

J. Parks, W. Parker, A. Rosenberg, 1989, Stroke.

Polymorphic variation in cytochrome oxidase subunit genes.

R. Swerdlow, W. Parker, J. Burns, 2010, Journal of Alzheimer's disease : JAD.

The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism.

J. Parks, D. Cassarino, J. Bennett, 1999, Biochimica et biophysica acta.

High frequency of mitochondrial complex I mutations in Parkinson’s disease and aging

J. Parks, W. Parker, W. Davis Parker, 2004, Neurobiology of Aging.

Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease.

N Howell, R. Davis, L. Thal, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties

W. Parker, Scott W. Miller, P. Trimmer, 1996, Journal of neurochemistry.

Electron transport chain defects in Alzheimer's disease brain

C. Filley, W. Parker, B. Kleinschmidt-DeMasters, 1994, Neurology.

The Role of T-Type Calcium Channel Genes in Absence Seizures

W. Parker, Yucai Chen, Keling Wang, 2014, Front. Neurol..

Developmental Changes in Newborn Lamb Brain Mitochondrial Activity and Postasphyxial Lipid Peroxidation

J. Parks, W. Parker, R. Sokol, 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Cytochrome C Oxidase in Alzheimer's Disease Brain

J. Parks, W. Parker, 1995, Neurology.

Oral ribavirin therapy for subacute sclerosing panencephalitis.

W. Parker, M. Levin, K. Mcintosh, 1989, The Journal of infectious diseases.

Reduced platelet cytochrome c oxidase activity in Alzheimer's disease

C. Filley, C. Cullum, J. Parks, 1994, Neurology.

Altered Calcium Homeostasis in Cells Transformed by Mitochondria from Individuals with Parkinson's Disease

Robert E. Davis, W. Parker, Scott W. Miller, 1997, Journal of neurochemistry.

Interaction Among Mitochondria, Mitogen‐Activated Protein Kinases, and Nuclear Factor‐κB in Cellular Models of Parkinson's Disease

R. Swerdlow, T. Sturgill, D. Cassarino, 2000, Journal of neurochemistry.

Alzheimer's disease cybrids replicate β‐amyloid abnormalities through cell death pathways

R. Swerdlow, J. Parks, D. Cassarino, 2000 .

Burkitt’s lymphoma: an unexpected cause of dental pain

W. Parker, K. Jones, 2021, Journal of surgical case reports.

Cytochrome Oxidase Deficiency in Alzheimer's Disease a

W. Parker, W D Parker, 1991, Annals of the New York Academy of Sciences.

Gender ratio differences between Parkinson's disease patients and their affected relatives.

R. Swerdlow, G. Wooten, J. Bennett, 2001, Parkinsonism & related disorders.

Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture

R. Swerdlow, J. Bennett, W. Parker, 2004, Neurobiology of Disease.

Use of Cytoplasmic Hybrid Cell Lines for Elucidating the Role of Mitochondrial Dysfunction in Alzheimer's Disease and Parkinson's Disease

Soumitra S Ghosh, R. Swerdlow, W. Parker, 1999, Annals of the New York Academy of Sciences.

Cytochrome Oxidase Inhibition: A Novel Animal Model of Alzheimer's Disease

D. Diamond, J. Parks, W. Parker, 1992, Journal of geriatric psychiatry and neurology.

Link between absence seizures and t-type calcium channels

W. Parker, Yucai Chen, 2015 .

Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis.

T. Prior, W. Parker, P. Allinson, 1998, Journal of medical genetics.

Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease

D. Turnbull, W. Parker, L. Bindoff, 1991, Journal of the Neurological Sciences.

MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE

D. Turnbull, W. Parker, L. Bindoff, 1989, The Lancet.

Mitochondrial ND5 mutations in idiopathic Parkinson's disease.

J. Parks, W. Parker, W Davis Parker, 2005, Biochemical and biophysical research communications.

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

J. Bennett, W. Parker, T. S. Smith, 1994, Neuroreport.

Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy

W. Parker, J. Holzbeierlein, Z. Hamilton, 2015, Bladder cancer.

Evidence for a defect in NADH

J. Parks, W. Parker, W D Parker, 1990, Neurology.

Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways.

R. Swerdlow, J. Parks, D. Cassarino, 2000, Annals of neurology.

Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies

W. Parker, P. Keeney, P. Trimmer, 2004, Journal of neurochemistry.

Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family

R. Swerdlow, G. Wooten, J. Parks, 1998, Annals of neurology.

Mitochondrial dysfunction in idiopathic Parkinson disease.

R. Swerdlow, W. Parker, W D Parker, 1998, American journal of human genetics.

A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy.

J. Parks, W. Parker, C. Oley, 1989, The New England journal of medicine.

Inhibition of Cytochrome Oxidase Impairs Learning and Hippocampal Plasticity: A Novel Animal Model of Alzheimer's Disease

D. Diamond, W. Parker, G. Rose, 1992 .

NMDA receptors increase OH radicals in vivo by using nitric oxide synthase and protein kinase C

J. Bennett, W. Parker, Byron Hammer, 1993, Neuroreport.

Biochemical Analysis of Cybrids Expressing Mitochondrial DNA from Contursi Kindred Parkinson's Subjects

R. Swerdlow, L. Golbe, G. Iorio, 2001, Experimental Neurology.

Mitochondrial DNA Rearrangement Spectrum in Brain Tissue of Alzheimer’s Disease: Analysis of 13 Cases

T. Beach, G. Serrano, W. Parker, 2016, PloS one.

Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients.

R. Swerdlow, J. Parks, D. Cassarino, 1999, Biochemical and biophysical research communications.

Evidence that two reports of mtDNA cytochrome c oxidase "mutations" in Alzheimer's disease are based on nDNA pseudogenes of recent evolutionary origin.

W. Parker, J. N. Davis, 1998, Biochemical and biophysical research communications.

Multiplex fluorescence-based primer extension method for quantitative mutation analysis of mitochondrial DNA and its diagnostic application for Alzheimer's disease.

E. Fahy, C. Herrnstadt, W. Parker, 1997, Nucleic acids research.

Aberrant mitochondrial RNA in the role of aging and aging associated diseases.

W. Parker, Yucai Chen, Hongyi Chen, 2015, Medical hypotheses.